StockTitan

@stocktitan.net

5 days ago

Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod Tivic Health Systems (Nasdaq:TIVC) received a formal Request for Information from the Ukrainian Ministry of Health on March 31, 2026, to evaluate Entolimod for potential inclusion in Ukraine's national strategic reserves against Acute Radiation Syndrome (ARS).The ministry also requested a pre-submission meeting. Tivic highlighted Entolimod's selective TLR5 mechanism that protects bone marrow and GI tissues, its potential in oncology supportive care, planned physician-sponsored trials later in 2026, and recent U.S. TechWatch meetings with BARDA on Jan 26 and Mar 10, 2026.

#TIVC Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod

www.stocktitan.net/news/TIVC/tivic-receives...

StockTitan

@stocktitan.net

1 week ago

U.S.-funded Tivic study targets deadly gut damage after radiation AFRRI will run the first mouse study, with NIAID covering all costs. Why it matters: Tivic gains non-dilutive support for an FDA Animal Rule path.

#TIVC Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome

www.stocktitan.net/news/TIVC/tivic-secures-...

StockTitan

@stocktitan.net

1 week ago

Tivic Reports Full Year 2025 Results Tivic (NASDAQ:TIVC) completed a strategic transformation into an immunotherapy company centered on Entolimod and next-generation Entolasta, acquiring exclusive global rights and related development assets.The company formed Velocity Bioworks CDMO, relocated headquarters to San Antonio, discontinued ClearUP consumer operations, and engaged U.S. government agencies for potential funding. 2025 operating expenses rose to $7.9M and cash totaled $12.6M at year-end.

#TIVC Tivic Reports Full Year 2025 Results

www.stocktitan.net/news/TIVC/tivic-reports-...

StockTitan

@stocktitan.net

1 week ago

Tivic Health CEO Letter to Shareholders Tivic Health Systems (Nasdaq:TIVC) announced a strategic pivot to focus solely on its TLR5 biopharma platform, centering on Entolimod and second-generation Entolasta. The company discontinued commercial sales of the ClearUP sinus device and suspended the non-invasive vagus stimulation program to concentrate resources on oncology supportive care and ARS preparedness.Manufacturing progress includes a reported 200-fold scale-up of Entolimod using 50-liter fermentation via Velocity Bioworks, its CDMO. Tivic said it is pursuing BARDA funding and allied-government stockpiling while exploring injectable and oral formulations. A year-end update will follow on March 25 with the Form 10-K filing.

#TIVC Tivic Health CEO Letter to Shareholders

www.stocktitan.net/news/TIVC/tivic-health-c...

StockTitan

@stocktitan.net

2 months ago

Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference Tivic Health (Nasdaq:TIVC) will present at the 3rd Annual DealFlow Discovery Conference on Jan 28-29, 2026 in Atlantic City. The CEO's presentation will outline a strategic pivot and forward outlook for advancing Entolimod™ toward commercialization.Key topics include cell line verification success, a demonstrated 200x manufacturing scale-up with reproducible quality, progress toward cGMP manufacturing in preparation for a Biologics License Application (BLA), engagement with BARDA via a Jan 26 TechWatch meeting, and the formation/integration of Velocity Bioworks, an internal CDMO aimed at accelerating commercial readiness.

#TIVC Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference

www.stocktitan.net/news/TIVC/tivic-to-showc...

StockTitan

@stocktitan.net

2 months ago

Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity Tivic Health (Nasdaq:TIVC) announced a 200x manufacturing scale-up for lead drug candidate Entolimod, completed by its wholly owned CDMO, Velocity Bioworks. Tivic validated a 50‑liter production batch equivalent to ~1.3 million human doses with purity, potency and yields meeting release criteria. The company said the acquisition of CDMO assets improved operational and cost efficiencies and expects to advance to 200 liters under cGMP as the next step toward a Biologics License Application (BLA) for Acute Radiation Syndrome (ARS). Tivic also noted an upcoming BARDA TechWatch meeting on January 26, 2026 to discuss strategic relevance.

#TIVC Tivic Delivers 200x Scale-up in Manufacturing for Lead Drug Candidate Entolimod(TM) And Achieves Reproducible Yields, Potency and Purity

www.stocktitan.net/news/TIVC/tivic-delivers...

StockTitan

@stocktitan.net

3 months ago

Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package Tivic (Nasdaq:TIVC) acquired cGMP manufacturing and development assets from Scorpius and launched Velocity Bioworks, a wholly owned CDMO subsidiary, to accelerate commercialization of Entolimod and serve third-party biotech customers. The company validated the Entolimod cell line at the site in Q3 and says the facility supports a BLA pathway.Financing led by 3i, LP includes $16M debt for the asset purchase, up to $75M in preferred convertible equity (including an $18M near-term tranche), and an expected $50M equity line of credit affiliate facility.

#TIVC Tivic Acquires Ready-to-Scale cGMP Manufacturing and Development Assets to Accelerate Commercialization of Entolimod; Tivic Growth Backed By $90M+ Financing Package

www.stocktitan.net/news/TIVC/tivic-acquires...

StockTitan

@stocktitan.net

4 months ago

#TIVC Tivic Secures Barda Meeting for Entolimod(TM) for Acute Radiation Syndrome

www.stocktitan.net/news/TIVC/tivic-secures-...

StockTitan

@stocktitan.net

4 months ago

Tivic Reports Third Quarter 2025 Financial Results Tivic Health (Nasdaq: TIVC) reported third quarter 2025 results on November 14, 2025 and outlined progress on its biologics transformation.Key points: Revenue $146,000 vs $126,000 year-ago; gross loss $145,000 driven by a $230,000 inventory reserve; operating expenses $2.3M; net loss $2.6M. At September 30, 2025 cash and equivalents were $3.5M and the company reported no debt and approximately $3.5M in committed funding.Corporate advances include transfer of two INDs for Entolimod, completion of cell line verification toward cGMP manufacturing, wind-down of the ClearUP consumer business, and $3.8M net proceeds from financing tranches in Q3.

#TIVC Tivic Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/TIVC/tivic-reports-...

StockTitan

@stocktitan.net

4 months ago

Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS) Tivic Health (NASDAQ:TIVC) reported results from a collaborative clinical optimization study with The Feinstein Institutes showing personalization of non-invasive cervical vagus nerve stimulation (ncVNS) parameters strongly affected autonomic outcomes on November 13, 2025.Key findings: personalizing stimulation frequency produced a 46% increase in heart rate variability (HRV) and was 8.9x more effective than a fixed frequency; optimal frequency varied between visits; electrode placement and configuration materially changed HRV; and 4 minutes of stimulation outperformed 20 minutes.The study used healthy subjects and the company said the data may inform development for multiple patient populations.

#TIVC Tivic Health Reports Findings of Clinical Optimization Trial of Non-Invasive Cervical Vagus Nerve Stimulation (ncVNS)

www.stocktitan.net/news/TIVC/tivic-health-r...

StockTitan

@stocktitan.net

4 months ago

#TIVC Tivic Expands Intellectual Property Portfolio

www.stocktitan.net/news/TIVC/tivic-expands-...

StockTitan

@stocktitan.net

5 months ago

Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23 Tivic Health (Nasdaq: TIVC) announced that CEO Jennifer Ernst will join a panel at the 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23 at 11:55 a.m. ET / 8:55 a.m. PT. The panel, titled "Building a Big Tent", will discuss advancing bioelectronic medicine by aligning stakeholders across healthcare, engaging first movers, and encouraging payor and pharma participation.Panelists include Scott Gottlieb, MD and John M. O’Brien, PharmD, with Allysia Finley moderating. The session focuses on cross-sector collaboration to accelerate adoption and impact of bioelectronic therapies.

#TIVC Tivic CEO, Jennifer Ernst, to Join Panel at 8th Annual Northwell Health Innovation Constellation Forum on Thursday, Oct. 23

www.stocktitan.net/news/TIVC/tivic-ceo-jenn...

StockTitan

@stocktitan.net

6 months ago

Critical Manufacturing Milestone: Tivic's Immunotherapy Entolimod Advances Toward FDA Biologics License Biotech firm Tivic Health completes cell line verification for Entolimod protein production with Scorpius Biomanufacturing, marking progress toward CGMP manufacturing and BLA filing.

#TIVC Tivic Completes Verification of Entolimod™ Cell Line: First Step in Establishing CGMP Manufacturing for BLA Filing

www.stocktitan.net/news/TIVC/tivic-complete...

StockTitan

@stocktitan.net

7 months ago

Breakthrough Radiation Treatment IND: Tivic Health's Entolimod Targets Both ARS and Advanced Cancer Programs Biotech firm Tivic Health receives two FDA INDs for Entolimod, advancing treatment for acute radiation syndrome and advanced cancers. Programs target ARS-H, ARS-GI, and cancer-related conditions.

#TIVC Tivic Receives Two Investigational New Drug Applications for Entolimod™ for the Treatment of Acute Radiation Syndrome (ARS) and Advanced Cancers

www.stocktitan.net/news/TIVC/tivic-receives...

StockTitan

@stocktitan.net

7 months ago

Military Radiation Protection: Tivic Health's Entolimod Draws Defense Agency Interest at MHSRS 2025 Tivic Health engages with BARDA, AFRRI, and MCDC at Military Health System Research Symposium to explore Entolimod deployment as radiation countermeasure for military personnel.

#TIVC Tivic Health Advances Discussions on Use of Entolimod as a Radiation Countermeasure at Military Health System Research Symposium 2025

www.stocktitan.net/news/TIVC/tivic-health-a...

StockTitan

@stocktitan.net

7 months ago

Tivic Reports Second Quarter 2025 Financial Results Tivic Health (NASDAQ: TIVC) reported Q2 2025 financial results, highlighting its strategic transformation from consumer healthtech to biopharmaceuticals. The company reported Q2 revenue of $86,000, down from $140,000 in Q2 2024, with a net loss of $1.9 million compared to $1.3 million in the prior year.Key developments include advancing their TLR5 agonist program Entolimod™ for ARS treatment, securing military interest, and expanding its worldwide license to include neutropenia treatment. The company plans to exit its ClearUP business by year-end and has secured financing through a $25 million equity line of credit and a preferred equity purchase agreement worth up to $8.4 million.Cash position stands at $1.2 million as of June 30, 2025, with $7.0 million remaining available through the preferred equity purchase agreement.

#TIVC Tivic Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/TIVC/tivic-reports-...

StockTitan

@stocktitan.net

8 months ago

Tivic Health Targets $21B Market with Radiation Treatment Drug Approval, Strengthens Leadership Team Shareholders greenlight Entolimod licensing for radiation treatment and neutropenia markets. Company projects $21B market opportunity by 2032. See strategic details.

#TIVC Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO

www.stocktitan.net/news/TIVC/tivic-sharehol...

StockTitan

@stocktitan.net

9 months ago

Breakthrough Study Reveals Personalization Key to Next-Gen $21B Vagus Nerve Treatment New findings unlock personalized vagus nerve stimulation approach in $21.3B market. Study reveals breakthrough parameters for non-invasive treatment. See full results.

#TIVC Tivic Health Completes Optimization Study for Its Non-Invasive Vagus Nerve Stimulation Device

www.stocktitan.net/news/TIVC/tivic-health-c...

StockTitan

@stocktitan.net

9 months ago

Tivic Health Announces Virtual-Only 2025 Shareholder Meeting: How to Participate Online Access Tivic Health's virtual annual meeting on June 30. Learn how to submit questions, voting requirements, and control number details. Get participation instructions.

#TIVC Tivic Health Announces 2025 Annual Meeting of Stockholders

www.stocktitan.net/news/TIVC/tivic-health-a...

StockTitan

@stocktitan.net

10 months ago

Tivic's $25M Backing Powers Major Pivot: Phase III Drug Catches Military Interest for Radiation Treatment Tivic secures $25M credit line and White House interest in Phase III Entolimod. Q1 reveals strategic expansion into defense-focused immunotherapeutics. See full pipeline.

#TIVC Tivic Reports First Quarter 2025 Financial Results and Provides Updates on Business Transformation

www.stocktitan.net/news/TIVC/tivic-reports-...

StockTitan

@stocktitan.net

10 months ago

Tivic Health Advances FDA Drug Application With $4.1M Manufacturing Deal for Revolutionary Radiation Treatment Tivic partners with Scorpius for GMP validation of Entolimod, advancing unique radiation syndrome treatment toward FDA submission. Learn manufacturing details.

#TIVC #SCPX Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

www.stocktitan.net/news/TIVC/tivic-health-e...

StockTitan

@stocktitan.net

10 months ago

Tivic Expands VNS Intellectual Property Portfolio Tivic Health Systems (NASDAQ: TIVC) has filed a new patent application (No. 63,801,058) titled "Vagus Nerve Stimulation System" with the USPTO, expanding its non-invasive VNS intellectual property portfolio. The patent protects methods for enhancing treatment efficacy through personalized stimulation parameters and electrode positioning, building on findings from their VNS optimization study.According to CSO Blake Gurfein, this technology is expected to deliver superior and more consistent therapeutic effects compared to current solutions. CEO Jennifer Ernst emphasized that protecting their IP is crucial as they advance their VNS program, highlighting Tivic's diverse portfolio of bioelectronic VNS and biologic immunotherapies for treating immune system dysregulation-related conditions.

#TIVC Tivic Expands VNS Intellectual Property Portfolio

www.stocktitan.net/news/TIVC/tivic-expands-...

Small Cap Strategist

@smcapstrategist.bsky.social

11 months ago

Small-cap stocks in new uptrend with average directional index, Tue Apr 22nd - #NG #YGMZ #TIVC #SMX #FER #DWTX #ALTS #SPWR #SLS #LAB #FWRG #CVGW #IIIN #FDP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

11 months ago

Exclusive: White House Backs Tivic Health's Breakthrough Military Defense Tech - FDA Fast Track Next? Key White House briefing reveals military potential for radiation treatment and neural tech. Two breakthrough candidates advance toward expedited FDA pathways. Get details.

#TIVC Tivic Health Reports White House Briefing and FDA Meetings Secured Positive Interest in Potential Military and Defense Applications of Its Product Candidates

www.stocktitan.net/news/TIVC/tivic-health-r...

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Most searched small-cap stocks, Thu Apr 3rd - #FSM #CORZ #GT #ALDX #IQ #TIVC #UAA #KSS #BBAI #BTE #WINT #WOLF #UUUU #UEC #SPCE #SMR #RGTI #QBTS #OSRH #NEOV - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Small Cap Strategist

@smcapstrategist.bsky.social

1 year ago

Small-cap stocks with strong volume gains, Wed Apr 2nd - #SONM #TIVC #IBG #VMAR #TCRT #SASR #RPAY #MBIO #HCWB #GLSI #CGNT #ANGO #VLN #FMBS #CLBR - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

1 year ago

Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth Tivic Health Systems (TIVC) reported its year-end 2024 financial results, marking a transformative period with strategic expansions in biotech. The company secured exclusive license rights to Entolimod™, a late-stage TLR5 agonist for treating acute radiation syndrome, and progressed in developing non-invasive cervical vagus nerve stimulation (ncVNS) devices.Key financial metrics for 2024 include:Revenue of $0.8M (down from $1.2M in 2023)Gross profit decreased to $2,000 (from $287,000 in 2023)Operating expenses reduced to $5.7M (from $8.5M in 2023)Net loss decreased 30% to $5.7M (from $8.2M in 2023)Cash and equivalents at $2.0M (down from $3.4M in 2023)Notable developments include securing a $25M equity line of credit, executing a 1-for-17 reverse stock split, and expanding their patent portfolio to 27 patents. The company plans to increase R&D investments in vagus nerve platform and advance TLR5 agonist programs.

#TIVC Tivic Reports Year End 2024 Financial Results and Provides Overview of Strategy for Transformation and Growth

www.stocktitan.net/news/TIVC/tivic-reports-...